Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: A claims-based study

Annals of General Psychiatry

Volumn 8, Issue , 2009, Pages

  Gianfrancesco, Frank D ^a   Pandina, Gahan ^b   Mahmoud, Ramy ^c   Wu, Jasmanda ^d   Wang, Ruey H ^a  

^a HECON Associates Inc   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JOHNSON AND JOHNSON   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; MEDICAID; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC ERROR; TREATMENT DURATION;

EID: 61849155362     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-8-5     Document Type: Article

References (20)

1. Conner P Fried G Hyperprolactinemia: Etiology, diagnosis, and treatment alternatives Acta Obstet Gynecol Scand 1998, 77:249-262 10.1034/ j.1600-0412.1998.770301.x 9539269
2. Goodnick PJ Rodriguez L Santana O Antipsychotics: Impact on prolactin levels Expert Opin Pharmacother 2002, 3:1381-1391 10.1517/ 14656566.3.10.1381 12387684
3. Petty RG Prolactin and antipsychotic medications: Mechanism of action Schizophr Res 1999, 35(Suppl):S67-S73 10.1016/S0920-9964(98)00158-3 10190227
4. Kinon BJ Gilmore JA Liu H Halbreich UM Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials Psychoneuroendocrinology 2003, 28(Suppl 2):69-82 10.1016/ S0306-4530(02)00128-2 12650682
5. Melkersson K Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenia patients J Clin Psychiatry 2005, 66:761-777 15960571
6. Montgomery J Winterbottom E Jessani M Kohegyi E Fulmer J Seamonds B Joriassen RC Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment J Clin Psychiatry 2004, 65:1491-1498 15554761
7. Kapur S Langlois X Vinken P Megens AA De Coster R Andrews JS The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats J Pharmacol Exp Ther 2002, 302:1129-1134 10.1124/jpet.102.035303 12183672
8. Szarfman A Tonning JM Levine JG Doraiswamy PM Atypical antipsychotics and pituitary tumors: A pharmacovigilance study Pharmacotherapy 2006, 26:748-758 10.1592/phco.26.6.748 16716128
9. Marder SR Essock SM Miller AL Buchanan RW Casey SE Davis JM Kane JM Lieberman JA Schooler NR Covell N Stroup S Weissman EM Wirshing DA Hall CS Pogach L Pi-Sunyer X Bigger JT Jr Friedman A Kleinber D Yevich SJ Davis B Schon S Physical health monitoring of patients with schizophrenia Am J Psychiatry 2004, 161:1334-1349 10.1176/ appi.ajp.161.8.1334 15285957
10. American Cancer Society Pituitary tumors http://documents.cancer.org/ 6028.00/6028.00.pdf
11. Ezzat S Asa SL Couldwell WT Barr CE Dodge WE Vance ML McCutcheon IE The prevalence of pituitary adenomas: A systematic review Cancer 2004, 101:613-619 10.1002/cncr.20412 15274075
12. Gianfrancesco FD Rajagopalan K Sajatovic M Wang RH Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics J Clin Psychiatry 2006 ,67:222-232 16566617
13. Gianfrancesco FD Grogg AL Mahmoud RA Wang RH Nasrallah HA Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database J Clin Psychiatry 2002, 63:920-930 12416602
14. Moore N Hall G Sturkenboom M Mann R Lagnaoui R Begaud B Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: The example of sertindole Pharmacoepidemiol Drug Saf 2003, 12(4):271-281 12812006 10.1002/pds.848
15. Chanson P Daujat F Young J Bellucci A Kujas M Doyon D Schaison G Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: A follow-up study J Clin Endocrinol Metab 2001, 86:3009-3015 10.1210/ jc.86.7.3009 11443160
16. Mavrakis AN Tritos NA Diagnostic and therapeutic approach to pituitary incidentalomas Endocr Pract 2004, 10:438-444 15760793
17. Hirsch W Zumkeller W Teichler H Jassov A Schlüter A Langer T Microadenomas of the pituitary gland in children with and without hypophyseal dysfunction in magnetic resonance imaging J Pediatr Endocrinol Metab 2002, 15:157-162 11874180
18. Kleinberg DL Davis JM de Coster R Van Baelen B Brecher M Prolactin levels and adverse events in patients treated with risperidone J Clin Psychopharmacol. 1999 Feb;19(1):57-61 1999, 19(1):57-61 9934944 10.1097/ 00004714-199902000-00011
19. Conley RR Mahmoud R A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder Am J Psychiatry 2001, 158:765-774 10.1176/appi.ajp.158.5.765 11329400
20. Potkin SG Gharabawi GM Greenspan AJ Mahmoud R Kosik-Gonzalez C Rupnow MF Bossie CA Davidson M Burtea V Zhu Y Trivedi JK A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization Schizophr Res 2006, 85:254-265 10.1016/j.schres.2006.03.027 16797162